Zai Lab rises as it teams up with Amgen for lung cancer drug trial

Amgen

01/04/2026 12:57

** U.S.-listed shares of biotech firm Zai Lab ZLAB.O rise 3.2% to $19.41 premarket

** Co says it will run a global early-stage study with Amgen AMGN.O to test a new drug combination for advanced small cell lung cancer, an aggressive form of lung cancer

** Study will evaluate Zai Lab's experimental drug zocilurtatug pelitecan with Amgen's Imdelltra, an already approved treatment in the U.S., in patients whose disease worsened after chemotherapy - ZLAB

** Co says Amgen will sponsor and lead the trial, while Zai Lab will supply its drug and keep full ownership

** Zai Lab says earlier studies showed its drug worked well, including against cancer spread to the brain, with manageable side effects

** Zai Lab says its drug has U.S. FDA orphan drug and fast track status

** Shares of Amgen up marginally premarket

** As of last close, ZLAB stock up ~7% & AMGN up ~8% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))